Evidence map›Paper›PMID 37859824›Full record

ArticleJournal of Cancer2023

Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer.

Alexandra Fischer, Anie Priscilla Masilamani, Susanne Schultze-Seemann, Isis Wolf, Christian Gratzke, Hendrik Fuchs, Philipp Wolf

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alexandra FischerDepartment of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
Anie Priscilla MasilamaniDepartment of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
Susanne Schultze-SeemannDepartment of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
Isis WolfDepartment of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
Christian GratzkeDepartment of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
Hendrik FuchsCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry; Berlin, Germany.
Philipp WolfDepartment of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
University of Freiburg · DEUniversity Medical Center Freiburg · DEHumboldt-Universität zu Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of advanced prostate cancer lacks specificity and curative intent. Therefore, the need for new targeted therapeutic approaches is high. In the present study, we generated the new targeted toxin EGF-PE24mutΔREDLK binding to the epidermal growth factor receptor (EGFR) on the surface of prostate cancer cells. It consists of the human epidermal growth factor (EGF) as binding domain and a de-immunized variant of

Indexed as

EGFEGFRendosomal escape enhancerprostate cancerSO1861targeted toxin

Identifiers

PMID37859824
PMCPMC10583583
OpenAlexW4387194505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.